Johnson & Johnson JNJ

271.22 0.54 0.20% as of 25 Sep
Market cap
$652.8B
P/E
31.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Johnson & Johnson (JNJ) EV/Sales

As of 25 September 2026, Johnson & Johnson (JNJ) trades at a EV/Sales of 6.8×. Over the past ten years it has ranged from 3.2× (August 2015) to 7.0× (September 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 5.5× 37.76%
FY2024 4.0× (16.80%)
FY2023 4.8× (18.83%)
FY2022 5.9× 3.65%
FY2021 5.7× 11.56%
FY2020 5.1× 6.63%
FY2019 4.8× 10.37%
FY2018 4.3× (14.31%)
FY2017 5.1× 22.33%
FY2016 4.1× 11.92%

Quarterly

Period EV/Sales Change
Jun 2026 6.4× 2.26%
Mar 2026 6.3× 14.13%
Dec 2025 5.5× 8.33%
Sep 2025 5.1× 18.50%
42 more quarters

Against its own ten years

Low 3.2× High 7.0×
Ten-year median 4.7×
Current reading's percentile 100

EV/Sales against peers

Company EV/Sales
PFE Pfizer Inc. compare 3.4×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.6×
MRK Merck & Co., Inc. compare 6.2×
JNJ Johnson & Johnson 6.8×
GILD Gilead Sciences, Inc. compare 6.9×
AMGN Amgen Inc. compare 7.0×
ABBV AbbVie Inc. compare 8.3×
LLY Eli Lilly and Company compare 13.8×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on JNJ